S100A8和S100A9的高表达与癌症患者较差的无病生存率相关：一项系统评价和荟萃分析。
High expression of S100A8 and S100A9 is associated with poor disease-free survival in patients with cancer: a systematic review and meta-analysis.
作者信息
Koh Hyun Min, Lee Hyun Ju, Kim Dong Chul
机构信息
Department of Pathology, Gyeongsang National University Changwon Hospital, Changwon, Republic of Korea.
Department of Pathology, Soonchunhyang University College of Medicine, Cheonan, Republic of Korea.
出版信息
Transl Cancer Res. 2021 Jul;10(7):3225-3235. doi: 10.21037/tcr-21-519.
BACKGROUND
The expression of S100A8 and S100A9 is found to be related with the survival of cancer patients, but the results and information regarding their prognostic significance are inconsistent in literature. This study, therefore, aimed to perform a comprehensive meta-analysis and determine the prognostic significance of S100A8 and S100A9 expression in patients with cancer.
METHODS
Data were collected by performing a literature search on the PubMed, Cochrane library, and Scopus databases. Pooled hazard ratio (HR) with confidence interval (CI) was calculated to assess the correlation between S100A8 and S100A9 expression and survival in patients with cancer.
RESULTS
In total, 5 studies that enrolled 735 cancer patients were included in the meta-analysis. The pooled HR concerning S100A8 and S100A9 expression was 1.98 (95% CI: 1.20-3.29, P=0.008) for disease-free survival (DFS), indicating an association between high expression of S100A8 and S100A9 and poor DFS in cancer patients. However, the expression of S100A8 and S100A9 was not significantly correlated with disease-specific survival (HR 1.71, 95% CI: 0.86-3.40, P=0.128).
DISCUSSION
The current meta-analysis revealed that S100A8 and S100A9 expression may be a potential prognosticator of DFS in cancer patients. The present systematic review is the first to investigate the survival outcomes of cancer patients with S100A8 and S100A9 expression.
背景
研究发现S100A8和S100A9的表达与癌症患者的生存率相关，但关于其预后意义的结果和信息在文献中并不一致。因此，本研究旨在进行一项全面的荟萃分析，并确定S100A8和S100A9表达在癌症患者中的预后意义。
方法
通过在PubMed、Cochrane图书馆和Scopus数据库上进行文献检索来收集数据。计算合并风险比（HR）及其置信区间（CI），以评估S100A8和S100A9表达与癌症患者生存率之间的相关性。
结果
荟萃分析共纳入了5项研究，涉及735例癌症患者。S100A8和S100A9表达的无病生存期（DFS）合并HR为1.98（95%CI：1.20-3.29，P=0.008），表明S100A8和S100A9高表达与癌症患者DFS较差有关。然而，S100A8和S100A9的表达与疾病特异性生存期无显著相关性（HR 1.71，95%CI：0.86-3.40，P=0.128）。
讨论
当前的荟萃分析表明，S100A8和S100A9表达可能是癌症患者DFS的潜在预后指标。本系统评价首次研究了S100A8和S100A9表达的癌症患者的生存结局。
Zotero 插件